Arenicin-1 vs Lixisenatide

Head-to-head comparison of Arenicin-1 (Arenicin-1) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyArenicin-1Lixisenatide
CategoryMarine-DerivedWeight Management
Full NameArenicin-1Exendin-4-derived GLP-1 receptor agonist
Molecular Weight2079 Da4858 Da
Half-Lifen/a2-4 hours
Amino Acids2144
Typical Dosen/a10-20 mcg daily
RoutepreclinicalSubcutaneous
Purity≥98%≥98%
Studies Count76400
Research StatusPre-clinicalApproved

Arenicin-1 Benefits

  • antimicrobial
  • anti-biofilm
  • membrane-active

Lixisenatide Benefits

  • postprandial glucose control
  • modest weight loss
  • appetite reduction
  • short-acting option

Arenicin-1 Dosing

bacterial infection|biofilm disruption

Lixisenatide Dosing

10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day

Arenicin-1 Side Effects

  • Arenicola marina

Lixisenatide Side Effects

  • nausea
  • vomiting
  • hypoglycemia when combined with insulin

Research Overview

Arenicin-1

Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.

Lixisenatide

Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Arenicin-1 stacks with:

Arenicola marinabeta-hairpinantibiotic

Lixisenatide stacks with:

basal-insulinmeal-plan
marine-derivedbioactiveantimicrobial peptidebiofilmGLP-1RAshort-actingpostprandial-controlweight-loss-adjacent